Rhenman & Partners Asset Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Rhenman & Partners Asset Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-701,707	Closed	-$1.8M	–	100
2024 Q2	$1.8M	Hold	701,707	–	–	0.17%	79
2024 Q1	$3.45M	Buy	701,707 +225,835	+47%	+$1.34M	0.33%	60
2023 Q4	$4.18M	Buy	475,872 +114,193	+32%	+$936K	0.42%	62
2023 Q3	$4.15M	Buy	361,679 +238,679	+194%	+$4.59M	0.45%	57
2023 Q2	$3.11M	Sell	123,000 -107,000	-47%	-$3.33M	0.33%	66
2023 Q1	$7.16M	Sell	230,000 -208,000	-47%	-$6.48M	0.79%	41
2022 Q4	$8.09M	Buy	438,000 +50,000	+13%	+$1.14M	0.84%	47
2022 Q3	$8.66M	Sell	388,000 -62,000	-14%	-$1.26M	0.91%	43
2022 Q2	$6.22M	Buy	450,000 +251,642	+127%	+$3.87M	0.71%	48
2022 Q1	$3.87M	Buy	+198,358	New	+$3.01M	0.38%	70
2021 Q4	–	Sell	-320,000	Closed	-$8.91M	–	96
2021 Q3	$8.91M	Buy	320,000 +50,000	+19%	+$1.43M	0.63%	51
2021 Q2	$8M	Buy	270,000 +50,000	+23%	+$1.44M	0.54%	62
2021 Q1	$6.15M	Hold	220,000	–	–	0.43%	67
2020 Q4	$6.24M	Hold	220,000	–	–	0.51%	59
2020 Q3	$5.53M	Hold	220,000	–	–	0.49%	61
2020 Q2	$5.37M	Hold	220,000	–	–	0.58%	60
2020 Q1	$3.26M	Sell	220,000 -30,000	-12%	-$621K	0.46%	62
2019 Q4	$4.06M	Buy	250,000 +76,083	+44%	+$1.18M	0.44%	68
2019 Q3	$2.26M	Sell	173,917 -19,264	-10%	-$236K	0.28%	72
2019 Q2	$2.51M	Hold	193,181	–	–	0.28%	70
2019 Q1	$3.04M	Hold	193,181	–	–	0.36%	68
2018 Q4	$3.89M	Sell	193,181 -10,000	-5%	-$220K	0.44%	62
2018 Q3	$5.05M	Hold	203,181	–	–	0.51%	63
2018 Q2	$5.58M	Hold	203,181	–	–	0.57%	59
2018 Q1	$6.26M	Buy	203,181 +20,601	+11%	+$663K	0.77%	49
2017 Q4	$6.53M	Sell	182,580 -63,820	-26%	-$1.83M	0.88%	47
2017 Q3	$6.79M	Buy	246,400 +26,400	+12%	+$640K	0.87%	45
2017 Q2	$5.81M	Buy	220,000 +10,000	+5%	+$223K	0.83%	47
2017 Q1	$4.37M	Hold	210,000	–	–	0.69%	54
2016 Q4	$4.35M	Hold	210,000	–	–	0.83%	47
2016 Q3	$3.4M	Sell	210,000 -10,000	-5%	-$145K	0.54%	65
2016 Q2	$2.99M	Buy	220,000 +50,000	+29%	+$884K	0.53%	63
2016 Q1	$2.97M	Sell	170,000 -3,000	-2%	-$61.1K	0.59%	61
2015 Q4	$5.91M	Buy	173,000 +25,000	+17%	+$867K	0.89%	44
2015 Q3	$4.4M	Sell	148,000 -24,000	-14%	-$729K	0.7%	55
2015 Q2	$5.5M	Sell	172,000 -64,000	-27%	-$1.65M	0.66%	51
2015 Q1	$4.89M	Buy	236,000 +109,426	+86%	+$1.89M	0.82%	43
2014 Q4	$2.14M	Buy	126,574 +21,319	+20%	+$372K	0.62%	71
2014 Q3	$2.04M	Buy	105,255 +23,255	+28%	+$606K	0.6%	67
2014 Q2	$2.79M	Buy	82,000 +32,865	+67%	+$1.03M	0.83%	42
2014 Q1	$1.55M	Buy	+49,135	New	+$1.54M	0.46%	74

Other funds holding RVNC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

Rhenman & Partners Asset Management's RVNC Position: Q3 2024 in Review

Rhenman & Partners Asset Management sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2024, closing a stake of 701,707 shares — an estimated $1.8M sold.

Rhenman & Partners Asset Management first reported a position in RVNC in Q1 2014 and held it in 41 quarters. The position peaked at $8.91M in Q3 2021. 201 funds tracked by Wall St. Rank hold RVNC as of Q3 2024.

Rhenman & Partners Asset Management reported no remaining Revance Therapeutics, Inc. position as of Q3 2024 after selling out during the quarter.
Rhenman & Partners Asset Management sold 701,707 Revance Therapeutics, Inc. shares in Q3 2024, an estimated $1.8M.
Rhenman & Partners Asset Management first reported a position in Revance Therapeutics, Inc. in Q1 2014 and held it in 41 quarters.
Rhenman & Partners Asset Management's Revance Therapeutics, Inc. position peaked at $8.91M in Q3 2021.
201 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2024.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2024, filed 13 Nov 2024.